MedPath

Sepiapterin

Generic Name
Sepiapterin
Drug Type
Small Molecule
Chemical Formula
C9H11N5O3
CAS Number
17094-01-8
Unique Ingredient Identifier
CJQ26KO7HP
Background

Sepiapterin is under investigation in clinical trial NCT03519711 (A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia).

A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

Phase 3
Recruiting
Conditions
Phenylketonuria
Interventions
First Posted Date
2024-03-08
Last Posted Date
2025-04-29
Lead Sponsor
PTC Therapeutics
Target Recruit Count
56
Registration Number
NCT06302348
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Indiana University, Indianapolis, Indiana, United States

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

Phase 3
Recruiting
Conditions
Phenylketonuria
Interventions
First Posted Date
2021-12-21
Last Posted Date
2025-05-08
Lead Sponsor
PTC Therapeutics
Target Recruit Count
200
Registration Number
NCT05166161
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital Colorado, Aurora, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

Indiana University School of Medicine Department of Medical and Molecular Genetics, Indianapolis, Indiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Utah, Salt Lake City, Utah, United States

and more 42 locations

A Study of PTC923 in Participants With Phenylketonuria

Phase 3
Completed
Conditions
Phenylketonuria
Interventions
Drug: Placebo
First Posted Date
2021-10-29
Last Posted Date
2024-01-10
Lead Sponsor
PTC Therapeutics
Target Recruit Count
157
Registration Number
NCT05099640
Locations
๐Ÿ‡ซ๐Ÿ‡ท

Bretonneau Hospital - CHRU de Tours, Tours, Centre-Val De Loire, France

๐Ÿ‡บ๐Ÿ‡ธ

Boston Children's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States

and more 40 locations

A Study of CNSA-001 in Women With Diabetic Gastroparesis

Phase 2
Completed
Conditions
Gastroparesis
Interventions
Drug: Placebo
First Posted Date
2018-10-19
Last Posted Date
2022-01-05
Lead Sponsor
PTC Therapeutics
Target Recruit Count
21
Registration Number
NCT03712124
Locations
๐Ÿ‡บ๐Ÿ‡ธ

GW Research, Inc., Chula Vista, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

LMG Research, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Johns Hopkins University, Baltimore, Maryland, United States

and more 3 locations

A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia

Phase 1
Completed
Conditions
BH4 Deficiency
Hyperphenylalaninemia
Interventions
First Posted Date
2018-05-09
Last Posted Date
2023-11-14
Lead Sponsor
PTC Therapeutics
Target Recruit Count
8
Registration Number
NCT03519711
Locations
๐Ÿ‡บ๐Ÿ‡ธ

UT Southwestern, Dallas, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Minnesota, Minneapolis, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Utah Hospital, Salt Lake City, Utah, United States

and more 1 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath